Effect of interferon-α therapy on epitope-specific cytotoxic T lymphocyte responses in hepatitis C virus-infected individuals

European Journal of Immunology

Volumn 32, Issue 1, 2002, Pages 144-154

  Vertuani, Simona ^a   Bazzaro, Martina ^a   Gualandi, Guido ^b   Micheletti, Fabiola ^a   Marastoni, Mauro ^a   Fortini, Cinzia ^a   Canella, Alessandro ^a   Marino, Michele ^b   Tomatis, Roberto ^a   Traniello, Serena ^a   Gavioli, Riccardo ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY HOSPITAL OF FERRARA   (Italy)

Author keywords

CTL; Epitope; Hepatitis C virus; IFN; Immunodominance

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; EPITOPE; MAJOR HISTOCOMPATIBILITY ANTIGEN; PEPTIDE; RECOMBINANT ALPHA2 INTERFERON; RECOMBINANT ALPHA2B INTERFERON; STIMULATORY GUANINE NUCLEOTIDE BINDING PROTEIN; VIRUS ANTIGEN;

ACUTE HEPATITIS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG RESPONSE; HEPATITIS C; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INFECTION CONTROL; LONGITUDINAL STUDY; PRIORITY JOURNAL;

ADULT; ANTIGENS, VIRAL; ANTIVIRAL AGENTS; CELL LINE; EPITOPES, T-LYMPHOCYTE; FEMALE; HEPACIVIRUS; HEPATITIS C; HEPATITIS C, CHRONIC; HLA-A2 ANTIGEN; HUMANS; INTERFERON ALFA-2B; INTERFERON-ALPHA; MALE; MIDDLE AGED; PEPTIDES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0036149967     PISSN: 00142980     EISSN: None     Source Type: Journal    
DOI: 10.1002/1521-4141(200201)32:1<144::AID-IMMU144>3.0.CO;2-X     Document Type: Article

References (49)

1. Immunopathogenesis of hepatitis C virus infection
2. Analysis of a successful immune response against hepatitis C virus
3. Analysis of successful immune responses in persons infected with hepatitis C virus
4. Different clinical behaviours of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell mediated immune response
5. + T lymphocyte responses are induced during the acute hepatitis C virus infection but are not sustained
6. Vigorous peripheral blood cytotoxic T cell response during the acute phase of hepatitis C virus infection
7. Intrahepatic cytotoxic T lymphocytes specific for hepatitis C virus in persons with chronic hepatitis
8. Cytotoxic T lymphocyte response to hepatitis C virus-derived peptides containing the HLA A2.1 binding motif
9. Quantitative analysis of the peripheral blood cytotoxic T lymphocyte response in patients with chronic hepatitis C virus infection
10. HLA class I-restricted cytotoxic T lymphocytes specific for hepatitis C virus
11. Liver-derived CTL in hepatitis C virus infection: Breadth and specificity of responses in a cohort of persons with chronic infection
12. The role of hepatitis C virus-specific cytotoxic T lymphocytes in chronic hepatitis C
13. Detection of diverse hepatitis C virus (HCV)-specific cytotoxic T lymphocytes in peripheral blood of infected persons by screening for responses to all translated proteins of HCV
14. Patients with chronic hepatitis C have circulating cytotoxic T cells which recognize hepatitis C virus-encoded peptides binding to HLA-A2.1 molecules
15. CTL responses of HLA-A2.1-transgenic mice specific for hepatitis C viral peptides predict epitopes for CTL of humans carrying HLA-A2.1
16. Use of recombinant protein to identify a motif-negative human cytotoxic T cell epitope presented by HLA-A2 in the hepatitis C virus NS3 region
17. Identification of A2-restricted hepatitis C virus-specific cytotoxic T lymphocyte epitopes from conserved regions of the viral genome
18. Identification of HLA-A3 and -B7-restricted CTL responses to hepatitis C virus in patients with acute and chronic hepatitis C
19. + T cells in hepatitis C virus-exposed healthy seronegative donors
20. + T cells: Implications for vaccine development
21. The function of type I interferons in antimicrobial immunity
22. Activation of epitope-specific memory cytotoxic T lymphocyte responses by synthetic peptides
23. The lifespan of MHC class I/complexes determines the efficiency of cytotoxic T lymphocyte responses
24. Selective amino acid substitutions of a subdominant Epstein-Barr virus LMP2-derived epitope increase HLA/peptide complex stability and immunogenicity: Implications for immunotherapy of Epstein-Barr virus-associated malignancies
25. Determinant selection of major histocompatibility complex class I-restricted antigenic peptides is explained by class I-peptide affinity and is strongly influenced by nondominant anchor residues
26. Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability
27. A single specific amino acid residue in peptide antigens is sufficient to activate memory cytotoxic T lymphocytes: Potential role of cross-reactive peptides in memory T cell maintenance
28. Differential cytotoxic T-lymphocyte responsiveness to the hepatitis B and C viruses in chronically infected patients
29. + T cells with type 1 or type 2 cytokine profile are related to different disease activity in chronic hepatitis C virus infection
30. Interferon-alpha (IFN-α) enhances cytotoxicity in healthy volunteers and chronic hepatitis C infection mainly by the perforin pathway
31. Interferon-α and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells
32. Selective expression of an interleukin-12 receptor component in human T helper 1 cells
33. IFN-α2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis Bacillus Calmette-Guerin immunotherapy
34. Degradation of cell proteins and the generation of MHC class I-presented peptides
35. IFN-γ exposes a cryptic cytotoxic T lymphocyte epitope in HIV-1 reverse transcriptase
36. Contribution of proteasome-mediated proteolysis to the hierarchy of epitopes presented by major histocompatibility complex class I molecules
37. Peptide-induced antiviral protection by cytotoxic T cells
38. Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with free synthetic peptide
39. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells
40. Peptide engineering allows cytotoxic T cell vaccination against human papilloma virus tumour antigen, E6
41. Amino-terminal alteration of the HLA-A0201-restricted human immunodeficiency virus pol peptide increases complex stability and in vitro immunogenicity
42. The effect of anchor residue modifications on the stability of major histocompatibility complex class I-peptide interactions
43. Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry
44. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains
45. Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules
46. Enhanced in vitro potency and in vivo immunogenicity of CTL epitope from hepatitis C virus protein following amino acid replacement at secondary HLA-A2.1 binding position
47. Multiple HLA A11-restricted cytotoxic T-lymphocyte epitopes of different immunogenicities in the Epstein-Barr virus-encoded nuclear antigen 4
48. Supra-agonist peptides enhance the reactivation of memory cytotoxic T lymphocyte responses
49. Recognition of the Epstein-Barr virus-encoded nuclear antigens EBNA-4 and EBNA-6 by HLA A11 restricted cytotoxic T lymphocytes: Implications for the down-regulation of HLA A11 in Burkitt's lymphoma